ClinVar Miner

Submissions for variant NM_000487.6(ARSA):c.1055A>G (p.Asn352Ser) (rs2071421)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000078931 SCV000110791 other not provided 2018-07-24 criteria provided, single submitter clinical testing
PreventionGenetics,PreventionGenetics RCV000249834 SCV000304453 benign not specified criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000020310 SCV000439433 likely benign Metachromatic leukodystrophy 2016-06-14 criteria provided, single submitter clinical testing
Center for Pediatric Genomic Medicine,Children's Mercy Hospital and Clinics RCV000078931 SCV000511542 benign not provided 2016-10-11 criteria provided, single submitter clinical testing
SIB Swiss Institute of Bioinformatics RCV000020310 SCV000883252 benign Metachromatic leukodystrophy 2018-10-15 criteria provided, single submitter curation This variant is interpreted as Benign - Stand Alone, for Metachromatic leukodystrophy, autosomal recessive. The following ACMG Tag(s) were applied: BA1 => Allele frequency is >5% in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. BP4 => Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.). BS3 => Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing ( (
Mendelics RCV000020310 SCV001141462 likely benign Metachromatic leukodystrophy 2019-05-28 criteria provided, single submitter clinical testing
OMIM RCV000003191 SCV000023349 benign ARYLSULFATASE A POLYMORPHISM 1997-12-01 no assertion criteria provided literature only
GeneReviews RCV000020310 SCV000040685 benign Metachromatic leukodystrophy 2014-02-06 no assertion criteria provided literature only Pseudodeficiency. Homozygosity for the p.Asn350Ser variant alone results in 50% or more of the mean control ARSA enzyme activity in leukocytes.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.